INmune Bio Inc

-0.13 (-1.55%)
Company Name Stock Ticker Symbol Market Type
INmune Bio Inc INMB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.13 -1.55% 8.25 19:59:17
Open Price Low Price High Price Close Price Prev Close
8.37 8.12 8.6221 8.25 8.38
more quote information »

Recent News

Date Time Source Heading
5/24/202309:00GLOBEINmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell,..
5/12/202308:01EDGARCurrent Report Filing (8-k)
5/08/202308:00GLOBEINmune Bio, Inc. Announces FDA Clearance of IND Application..
5/04/202316:01EDGARCurrent Report Filing (8-k)
5/03/202316:10GLOBEINmune Bio Inc. Announces First Quarter 2023 Results and..
5/03/202316:02EDGARQuarterly Report (10-q)
4/24/202309:00GLOBEINmune Bio, Inc. to Report First Quarter 2023 Financial..
4/21/202316:02EDGARProxy Statement (definitive) (def 14a)
4/19/202308:30GLOBEXPro1595 Improves Outcomes in a Mouse Model of TBI-induced..
4/11/202316:01EDGARCurrent Report Filing (8-k)
4/11/202308:00GLOBEINmune Bio, Inc. to Present Preclinical Data at the 2023..
4/03/202309:13EDGARCurrent Report Filing (8-k)
4/03/202309:00GLOBEINmune Bio, Inc. Announces Submission of Investigational New..
3/15/202316:04EDGARCurrent Report Filing (8-k)
3/03/202316:48EDGARCurrent Report Filing (8-k)
3/02/202316:05GLOBEINmune Bio, Inc. Announces 2022 Results and Provides..
2/22/202316:01EDGARCurrent Report Filing (8-k)
2/22/202316:01EDGARCurrent Report Filing (8-k)
2/21/202316:10EDGARStatement of Changes in Beneficial Ownership (4)
2/21/202316:08EDGARStatement of Changes in Beneficial Ownership (4)
2/21/202316:07EDGARStatement of Changes in Beneficial Ownership (4)
2/21/202316:05EDGARStatement of Changes in Beneficial Ownership (4)
2/21/202316:04EDGARStatement of Changes in Beneficial Ownership (4)
2/21/202316:03EDGARStatement of Changes in Beneficial Ownership (4)
2/21/202309:00GLOBEINmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022..
2/10/202306:11EDGARCurrent Report Filing (8-k)
2/08/202308:45GLOBEINmune Bio, Inc. Receives Approximately $6.4 Million in..
1/25/202309:08EDGARCurrent Report Filing (8-k)
1/25/202307:45GLOBEINmune Bio, Inc. Announces Pre-Clinical Data That Support a..
12/22/202216:01EDGARCurrent Report Filing (8-k)
12/22/202208:00GLOBEINmune Bio, Inc., Virginia Commonwealth University, and..
12/12/202217:04EDGARCurrent Report Filing (8-k)
12/09/202216:01EDGARCurrent Report Filing (8-k)
12/09/202213:55TRMNMaxim Group Keeps Their Buy Rating on Inmune Bio (INMB)
12/08/202208:00GLOBEINmune Bio, Inc. Data at ASH Highlight Innovative Natural..
12/07/202216:02EDGARCurrent Report Filing (8-k)
12/06/202216:00GLOBEINmune Bio, Inc. Reports Combination Therapy with INB03™..
11/29/202208:00GLOBEINmune Bio, Inc. Focused on Novel Clinical Trial Designs to..
11/14/202209:00GLOBEINmune Bio, Inc. Receives Health Canada “No Objection..
11/04/202216:44EDGARCurrent Report Filing (8-k)
11/04/202210:05TRMNMaxim Group Remains a Buy on Inmune Bio (INMB)
11/02/202216:00GLOBEINmune Bio, Inc. Announces Third Quarter 2022 Results and..
10/26/202208:16EDGARCurrent Report Filing (8-k)
10/26/202208:10GLOBEINmune Bio, Inc. to Report Third Quarter 2022 Financial..
10/19/202208:08EDGARCurrent Report Filing (8-k)
10/19/202208:00GLOBEINmune Bio, Inc. Announces Positive Solid Tumor Efficacy..
9/07/202216:01EDGARCurrent Report Filing (8-k)
9/07/202209:00GLOBEINmune Bio, Inc. to Present at the H.C. Wainwright 24th..
8/05/202208:40TRMNMaxim Group Keeps Their Buy Rating on Inmune Bio (INMB)
8/03/202216:10GLOBEINmune Bio, Inc. Announces Second Quarter 2022 Results and ..